More than one-third of adults report delaying or forgoing health care either because of fear of infection or their physicians offering limited services.
Astudy by the Urban Institute, a nonprofit health policy center, found that more than one-third of adults between the ages of 18 and 64 have forgone or delayed medical care because of the coronavirus disease 2019 (COVID-19) pandemic.1 According to the report, as of September 2020, 36% of adults reported delaying or forgoing health care because they were worried about becoming infected with COVID-19 or because their providers offered limited services because of the pandemic.
Among respondents with 1 or more chronic condition, 40.7% reported they have delayed or forgone care, whereas 56.3% of respondents with both a physical and a mental health condition have done the same, the report says. Black adults were more likely (39.7%) to report forgoing or delaying care than Hispanic/Latinx (35.5%) or White (34.3%) adults and more likely to report forgoing or delaying multiple types of care, at 28.5% compared with 22.3% and 21.1% respectively, according to the report.
The most common type of medical care delayed or forgone was dental at 25.3%, followed by visiting a primary care physician or specialist at 20.6%, and receiving preventive health screenings or medical tests at 15.5%, the report says.
Respondents with 1 or more chronic health conditions such as cancer, hypertension, diabetes, respiratory illness, heart disease, kidney disease, and mental health disorders made up the majority (76%) of those who have delayed or forgone health care. Delaying and forgoing care is not without its dangers; 32.6% of respondents say that doing so has worsened 1 or more of their health conditions or limited their ability to work or do other daily activities, according to the report.
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.